Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Leaders, not CEOs

Cancer antibody play Igenica to reach clinic with $33M series C round

Leaders, not CEOs

Last week's $33 million series C round is expected to get cancer mAb

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE